Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IMVT |
---|---|---|
09:32 ET | 16627 | 38.97 |
09:33 ET | 3561 | 39.04 |
09:35 ET | 13858 | 38.78 |
09:37 ET | 7804 | 39.16 |
09:39 ET | 1872 | 39.08 |
09:42 ET | 13508 | 39.2 |
09:44 ET | 4550 | 39.2 |
09:46 ET | 4331 | 39.06 |
09:48 ET | 19062 | 39.06 |
09:50 ET | 27757 | 38.955 |
09:51 ET | 7326 | 38.995 |
09:53 ET | 1619 | 39.07 |
09:55 ET | 6173 | 39 |
09:57 ET | 7558 | 38.905 |
10:00 ET | 9690 | 38.875 |
10:02 ET | 2840 | 38.93 |
10:04 ET | 58793 | 39 |
10:06 ET | 10743 | 38.835 |
10:08 ET | 5517 | 38.7 |
10:09 ET | 3929 | 38.87 |
10:11 ET | 20791 | 38.57 |
10:13 ET | 5273 | 38.5901 |
10:15 ET | 3385 | 38.49 |
10:18 ET | 7725 | 38.415 |
10:20 ET | 21068 | 38.175 |
10:22 ET | 19192 | 38.26 |
10:24 ET | 9962 | 38.645 |
10:26 ET | 12360 | 38.745 |
10:27 ET | 3902 | 38.694 |
10:29 ET | 7439 | 38.475 |
10:31 ET | 3993 | 38.59 |
10:33 ET | 6694 | 38.47 |
10:36 ET | 9524 | 38.5 |
10:38 ET | 4778 | 38.44 |
10:40 ET | 7073 | 38.495 |
10:42 ET | 3740 | 38.5 |
10:44 ET | 3147 | 38.345 |
10:45 ET | 6499 | 38.46 |
10:47 ET | 3713 | 38.54 |
10:49 ET | 8520 | 38.44 |
10:51 ET | 3548 | 38.425 |
10:54 ET | 7353 | 38.5 |
10:56 ET | 9342 | 38.54 |
10:58 ET | 18929 | 38.36 |
11:00 ET | 10207 | 38.445 |
11:02 ET | 13296 | 38.375 |
11:03 ET | 6331 | 38.42 |
11:05 ET | 7229 | 38.765 |
11:07 ET | 4441 | 38.885 |
11:09 ET | 4167 | 39.175 |
11:12 ET | 8532 | 39.25 |
11:14 ET | 22870 | 38.93 |
11:16 ET | 13964 | 38.98 |
11:18 ET | 6910 | 39.23 |
11:20 ET | 1875 | 39.27 |
11:21 ET | 14689 | 39.02 |
11:23 ET | 2300 | 39.01 |
11:25 ET | 6658 | 39.11 |
11:27 ET | 4688 | 39.1321 |
11:30 ET | 7021 | 39.27 |
11:32 ET | 13009 | 39.21 |
11:34 ET | 5681 | 39.08 |
11:36 ET | 7972 | 38.97 |
11:38 ET | 4169 | 39.03 |
11:39 ET | 2882 | 39.085 |
11:41 ET | 1763 | 39.09 |
11:43 ET | 10134 | 39.05 |
11:45 ET | 15021 | 39.123 |
11:48 ET | 51298 | 39.2 |
11:50 ET | 8952 | 39.02 |
11:52 ET | 3798 | 39.27 |
11:54 ET | 3436 | 39.25 |
11:56 ET | 5309 | 39.33 |
11:57 ET | 8605 | 39.245 |
11:59 ET | 10454 | 39.143 |
12:01 ET | 4403 | 39.1 |
12:03 ET | 6001 | 39.03 |
12:06 ET | 4470 | 39.12 |
12:08 ET | 4892 | 39.29 |
12:10 ET | 1874 | 39.21 |
12:12 ET | 5148 | 39.19 |
12:14 ET | 5265 | 39.265 |
12:15 ET | 5366 | 39.205 |
12:17 ET | 10538 | 39.19 |
12:19 ET | 10271 | 39.35 |
12:21 ET | 4347 | 39.3 |
12:24 ET | 1385 | 39.37 |
12:26 ET | 2877 | 39.3694 |
12:28 ET | 2955 | 39.42 |
12:30 ET | 3775 | 39.51 |
12:32 ET | 3269 | 39.64 |
12:33 ET | 5242 | 39.76 |
12:35 ET | 2092 | 39.74 |
12:37 ET | 1872 | 39.72 |
12:39 ET | 3034 | 39.845 |
12:42 ET | 11773 | 39.95 |
12:44 ET | 7677 | 39.88 |
12:46 ET | 2892 | 39.905 |
12:48 ET | 5202 | 39.98 |
12:50 ET | 4693 | 40.01 |
12:51 ET | 1219 | 39.97 |
12:53 ET | 6746 | 39.96 |
12:55 ET | 5581 | 40.13 |
12:57 ET | 2535 | 40.21 |
01:00 ET | 5212 | 39.9825 |
01:02 ET | 2300 | 39.98 |
01:04 ET | 5108 | 39.85 |
01:06 ET | 3285 | 39.755 |
01:08 ET | 2199 | 39.81 |
01:09 ET | 29808 | 39.59 |
01:11 ET | 5349 | 39.835 |
01:13 ET | 8190 | 39.76 |
01:15 ET | 7529 | 39.7 |
01:18 ET | 4137 | 39.68 |
01:20 ET | 9739 | 39.7 |
01:22 ET | 5703 | 39.765 |
01:24 ET | 3601 | 39.79 |
01:26 ET | 921 | 39.85 |
01:27 ET | 3087 | 39.76 |
01:29 ET | 3070 | 39.74 |
01:31 ET | 4488 | 39.77 |
01:33 ET | 5425 | 39.86 |
01:36 ET | 3531 | 39.96 |
01:38 ET | 7013 | 39.93 |
01:40 ET | 3497 | 39.97 |
01:42 ET | 8565 | 40.03 |
01:44 ET | 4341 | 40.04 |
01:45 ET | 3794 | 40.05 |
01:47 ET | 4591 | 40.04 |
01:49 ET | 7395 | 39.91 |
01:51 ET | 9100 | 39.98 |
01:54 ET | 12124 | 40.05 |
01:56 ET | 800 | 40.03 |
01:58 ET | 17025 | 40 |
02:00 ET | 3581 | 40.085 |
02:02 ET | 12584 | 40.06 |
02:03 ET | 3525 | 40.195 |
02:05 ET | 22806 | 40.03 |
02:07 ET | 2595 | 40.06 |
02:09 ET | 2978 | 40.1 |
02:12 ET | 3181 | 40.025 |
02:14 ET | 967 | 40.045 |
02:16 ET | 8093 | 40.03 |
02:18 ET | 2567 | 40.05 |
02:20 ET | 22252 | 39.97 |
02:21 ET | 5295 | 40 |
02:23 ET | 1384 | 39.985 |
02:25 ET | 1801 | 39.9715 |
02:27 ET | 10405 | 40.035 |
02:30 ET | 2172 | 40.04 |
02:32 ET | 12075 | 40.05 |
02:34 ET | 4000 | 40.19 |
02:36 ET | 4249 | 40.285 |
02:38 ET | 3151 | 40.26 |
02:39 ET | 1837 | 40.28 |
02:41 ET | 8484 | 40.2776 |
02:43 ET | 18778 | 40.135 |
02:45 ET | 3700 | 40.28 |
02:48 ET | 6721 | 40.34 |
02:50 ET | 34103 | 40.345 |
02:52 ET | 1415 | 40.305 |
02:54 ET | 7041 | 40.3415 |
02:56 ET | 3453 | 40.31 |
02:57 ET | 7968 | 40.34 |
02:59 ET | 2078 | 40.42 |
03:01 ET | 619 | 40.4225 |
03:03 ET | 21824 | 40.41 |
03:06 ET | 98046 | 40.345 |
03:08 ET | 9601 | 40.32 |
03:10 ET | 1320 | 40.335 |
03:12 ET | 6174 | 40.38 |
03:14 ET | 2610 | 40.45 |
03:15 ET | 2278 | 40.46 |
03:17 ET | 1231 | 40.42 |
03:19 ET | 3811 | 40.57 |
03:21 ET | 37918 | 40.56 |
03:24 ET | 4830 | 40.485 |
03:26 ET | 4802 | 40.575 |
03:28 ET | 9901 | 40.55 |
03:30 ET | 7027 | 40.575 |
03:32 ET | 4640 | 40.5539 |
03:33 ET | 12731 | 40.52 |
03:35 ET | 8164 | 40.475 |
03:37 ET | 4762 | 40.4 |
03:39 ET | 9890 | 40.37 |
03:42 ET | 5910 | 40.34 |
03:44 ET | 12275 | 40.34 |
03:46 ET | 7525 | 40.36 |
03:48 ET | 12294 | 40.45 |
03:50 ET | 8013 | 40.49 |
03:51 ET | 25381 | 40.46 |
03:53 ET | 18906 | 40.48 |
03:55 ET | 25174 | 40.59 |
03:57 ET | 37071 | 40.54 |
04:00 ET | 230852 | 40.55 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Immunovant Inc | 5.7B | -20.7x | --- |
CRISPR Therapeutics AG | 5.3B | -15.3x | --- |
Vaxcyte Inc | 4.9B | -16.3x | --- |
Ascendis Pharma A/S | 5.8B | -8.9x | --- |
Cerevel Therapeutics Holdings Inc | 4.7B | -10.4x | --- |
BridgeBio Pharma Inc | 5.0B | -7.9x | --- |
Immunovant, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab (IMVT-1401), and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn. IMVT-1402 has also been observed in nonclinical studies to reduce IgG antibody levels. IMVT-1402 is delivered as a 2 mL simple subcutaneous injection.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.7B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 144.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-1.96 |
Book Value | $2.78 |
P/E Ratio | -20.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.